Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
ASLAN Pharmaceutical (ASLN) to present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference, offering a virtual company presentation by CEO Carl Firth. Institutional investors and industry participants can register to listen to the presentation and schedule one-on-one meetings with ASLAN management.
03/27/2024 - 08:07 AM
SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give a virtual company presentation at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders, to be held virtually on Thursday, March 28, 2024. ASLAN management will also be available for one-on-one meetings with investors on the day of the conference. Please register for the event via this link or contact your representative at H.C. Wainright to schedule a meeting.
Company Presentation Information
Format: Virtual presentation
Presenter: Carl Firth, CEO, ASLAN Pharmaceuticals
Date: Thursday, March 28, 2024
Time: 8:00 a.m. EDT
Institutional investors and industry participants are invited to register to listen to the presentation via this link . A copy of the presentation will be posted to the Investor Relations section of ASLAN’s website after the event.
About the H.C. Wainright Autoimmune and Inflammatory Disease Virtual Conference
The 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders features a full day of one-on-one investor meetings and company presentations by management of leading public and private companies with approved or novel therapies in development for treatment of various skin diseases. In addition, H.C. Wainwright will be hosting KOL calls to discuss emerging and new data presented at AAD Conference (March 8-12) and in-depth discussion on approved and more advanced therapies in development for varying skin diseases. Skin diseases are highly common with about 16.5M patients and 7.5M patients in the US with atopic dermatitis (AD) and psoriasis, respectively. Despite approved treatments in diseases like AD and psoriasis, there remains an unmet need for more convenient oral therapies, and for other diseases such as hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU), more effective therapies are needed. The conference aims to provide an immersive experience for institutional investors, venture capitalists, private equity firms, and industry executives who are involved with or particularly interested in novel and existing therapies to treat skin diseases.
About ASLAN Pharmaceuticals eblasakimab , a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study in moderate-to-severe AD patients. ASLAN is also developing farudodstat , a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a, proof-of-concept trial with an interim readout expected in mid-2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the ASLAN website or follow ASLAN on LinkedIn .
Media and IR contacts
ASLAN Pharmaceutical will present at the conference on Thursday, March 28, 2024.
The presenter at the virtual company presentation will be Carl Firth, CEO of ASLAN Pharmaceuticals.
Institutional investors and industry participants can register to listen to the presentation via the provided link.
Yes, a copy of the presentation will be posted to the Investor Relations section of ASLAN's website after the event.
ASLAN Pharmaceuticals Ltd
ASLN Rankings
#4588 Ranked by Stock Gains
ASLN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
Cayman Islands
City
190 Elgin Avenue
About ASLN
aslan pharmaceuticals (aslan, 6497.tt) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. aslan targets diseases that are both highly prevalent in asia and orphan indications in the united states and europe. led by a senior management team with extensive experience in global and regional development and commercialization, aslan is headquartered in singapore and has offices in taiwan and china. aslan’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. aslan’s partners include array biopharma, bristol-myers squibb, almirall and csl.
